Miltenyi Biomedicine Gmbh

This early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…

This phase 2 trial tests a new treatment called MB-CART2019.1 for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer c…

This study tests a new treatment called MB-CART2019.1 for people with active multiple sclerosis (MS) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified to target and attack harmful immune cells driving MS. The goal is to see if it …

This phase 2 trial is testing a new type of CAR-T cell therapy called MB-CART2019.1 in children and teens (ages 6 months to under 18) with B-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to atta…

This early-stage trial tests a new treatment for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack…

This phase 2 trial tests a new CAR T cell therapy called MB-CART2019.1 in 31 people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, genetically modified to target and k…

This trial is testing a treatment called MB-CART19.1, which uses a patient's own immune cells that are modified in a lab to target and destroy faulty cells involved in lupus. It is for adults with severe lupus that has not improved with standard treatments. The study will first f…

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effec…

This trial tests a one-time treatment using a patient's own immune cells, engineered to target and destroy B cells, which drive autoimmune diseases like lupus, scleroderma, and myositis. 24 adults with active disease will receive the therapy after a short chemotherapy. The main g…